← All trials
NCT05834478
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2023
- Primary completion
- Oct 31, 2026
- Completion date
- Dec 31, 2026
- First posted
- Apr 28, 2023
- Last posted
- Nov 15, 2023
- Enrollment
- 103
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Emory UniversityLead sponsor
- National Institute on Drug Abuse (NIDA)Collaborator
- Emory UniversityOverall official - principal investigator
- Emory UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.